5 Most Undervalued Healthcare Stocks to Buy Now

3. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

PE Ratio: 9.60

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the most undervalued healthcare stocks to buy now.

TheFly reported on April 7 that RBC Capital Markets revised its outlook on ACAD, lowering its price target from $30 to $29 while keeping an Outperform rating. The adjustment was included in a broader Biotech sector preview ahead of first-quarter results. The firm noted that seasonal pressures such as reimbursement adjustments, fewer operating days, and adverse weather conditions could weigh on near-term performance, particularly for newly launched and clinic-dependent products. However, it also highlighted that renewed merger and acquisition activity and greater clarity on limited impacts from pricing policy changes may help balance short-term volatility and support a constructive sector outlook.

On the same day, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the U.S. launch of Daybue Stix, an oral formulation of trofinetide now widely accessible for treating Rett syndrome in both adults and children aged two years and older.

The newly introduced version, previously cleared by the U.S. Food and Drug Administration in December 2025, delivers the same therapeutic effectiveness and safety profile as the original oral solution. It is designed to be bioequivalent while offering improved patient convenience through greater flexibility in dosing volume and taste options, supporting easier administration for individuals living with Rett syndrome.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company based in San Diego focused on CNS disorders and rare diseases. It is known for developing NUPLAZID for Parkinson’s disease psychosis and DAYBUE for Rett syndrome.